06-09-2021

Bold Therapeutics Receives Additional Funding to Support Development of BOLD-100 as a Novel Antiviral

05-11-2021

FDA Grants Bold Therapeutics’ BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer

04-16-2021

BOLD-100 Effective In Vitro Against COVID-19 Variants

04-09-2021

BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting

01-08-2021

Bold Therapeutics Secures Funding to Prepare BOLD-100 for COVID-19 Clinical Trials

01-06-2021

Bold Therapeutics Collaborators at University of Vienna Published Study Detailing the Binding Partners and Mechanism of Action of BOLD-100

12-18-2020

Bold Therapeutics COVID-19 Program Chosen by National Research Council of Canada for Development Support

10-09-2020

Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100

09-17-2020

BOLD-100 Shows Inhibition of DNA Repair Pathways in Breast Cancer

08-17-2020

BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model

07-15-2020

BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro

06-11-2020

 Bold Therapeutics Expands COVID-19 Consortium 

05-28-2020

Bold Therapeutics and Hana Pharm Execute Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea

04-15-2020

Bold Therapeutics and the University of Ottawa Initiate Research Partnership to Study BOLD-100 in the Treatment of COVID-19

03-27-2020

Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate Has Potential Utility in the Treatment of COVID-19

03-27-2020

Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in GI Cancers

02-10-2020

Bold Therapeutics Visiting Collaborators in Europe
View All